nebulized platelet lysate / Regenexx - LARVOL DELTA

Nebulized PL for Post-COVID-19 Syndrome (clinicaltrials.gov) - P=N/A | N=1 | Terminated | Sponsor: Regenexx, LLC | Trial completion date: Dec 2021 ➔ Jun 2021 | Active, not recruiting ➔ Terminated; Low enrollment

Trial completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Nebulized PL for Post-COVID-19 Syndrome (clinicaltrials.gov) - P=N/A; N=1; Active, not recruiting; Sponsor: Regenexx, LLC; Recruiting ➔ Active, not recruiting; N=40 ➔ 1

Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Nebulized PL for Post-COVID-19 Syndrome (clinicaltrials.gov) - P=N/A; N=40; Recruiting; Sponsor: Regenexx, LLC; Not yet recruiting ➔ Recruiting; Initiation date: Aug 2020 ➔ Dec 2020

Enrollment open • Trial initiation date • Infectious Disease • Novel Coronavirus Disease